Jaguar Health Seeks Shareholder Approval for Highly Dilutive Preferred Exchange, Warrant Repricing, and Equity Plan Expansion
JAGX is trading near its 52-week low of $0.95 (1.4% above the low).
Summary
Jaguar Health filed a preliminary proxy for a September 4 special meeting seeking approval for three highly dilutive actions: exchanging Series Q Preferred Stock for up to 90% more common shares, repricing warrants to $1.00 (adding 13% dilution), and expanding the equity plan to 14% of fully diluted shares.
Key Events · Corporate Governance and Compliance · JAGX
-
Series Q Exchange Could Add 90% More Shares
Proposal 1 seeks approval to issue up to 7,911,743 shares upon exchange of 889.28 Series Q Preferred shares. At a hypothetical $0.50 exchange price, 44.5 million shares would be issued — 90.2% of the current 4.86 million outstanding. Because the actual exchange price is the lower of the closing price or 5-day average before each exchange, dilution could be severe if the stock stays depressed.
-
Warrant Repricing Adds 13% Dilution, Forces Quick Exercise
Proposal 2 reprices 60,781 warrants from $35.00–$266.44 down to $1.00, and also entitles holders to 682,661 dividend shares from the Series O conversion. Total potential issuance is 745,354 shares (13.3% of outstanding). If approved, the warrants must be exercised within 30 days via cashless exercise, creating immediate selling pressure.
-
Equity Plan Expansion to 14% of Fully Diluted Shares
Proposal 3 amends the 2014 Stock Incentive Plan to increase the share reserve to 14% of fully diluted shares as of September 30, 2026. With only 10,591 shares currently available (0.17% of outstanding), the plan would otherwise run dry in Q3 2026. The new reserve will be calculated on a fully diluted basis including all convertible securities, meaning it could be substantial.
-
Special Meeting Set for September 4, 2026
Shareholders of record as of July 6, 2026 will vote on all three proposals at a special meeting in San Francisco. The board recommends voting FOR all proposals. Approval requires a majority of votes cast, except Proposal 1 where Series Q holders cannot vote.
Analysis · JAGX · Life Sciences
Shareholders face a triple threat of dilution as Jaguar Health puts three proposals to a vote. The first alone could swell the share count by up to 90% if the Series Q Preferred Stock is exchanged at a low price — the company's own example at $0.50 per share shows 44.5 million new shares on top of 4.86 million outstanding. A second proposal reprices deeply out-of-the-money warrants to $1.00, adding another 13% dilution, and forces a cashless exercise within 30 days of approval. The third reloads the equity incentive plan to 14% of fully diluted shares, ensuring management and employees can be compensated even as the share count balloons. With the stock already trading near its 52-week low of $0.95, these approvals would give the company the green light to issue shares at prices that could drive it even lower. The special meeting is set for September 4, 2026.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.95 to $92.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.